Farther Finance Advisors’s Standard BioTools LAB Stock Holding History

Farther Finance Advisors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$933	Buy	1,147 +816	+247%	+$771	﹤0.01%	5394
2026 Q1	$304	Buy	331 +323	+4,038%	+$391	﹤0.01%	5367
2025 Q4	$10	Buy	8 +3	+60%	+$4	﹤0.01%	5412
2025 Q3	$7	Hold	5	–	–	﹤0.01%	4929
2025 Q2	$6	Hold	5	–	–	﹤0.01%	4465
2025 Q1	$5	Sell	5 -18	-78%	-$25	﹤0.01%	4238
2024 Q4	$40	Hold	23	–	–	﹤0.01%	3886
2024 Q3	$44	Sell	23 -9	-28%	-$18	﹤0.01%	3870
2024 Q2	$55	Hold	32	–	–	﹤0.01%	3683
2024 Q1	$86	Buy	+32	New	+$77	﹤0.01%	3401

Other funds holding LAB

MAM

Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

WETS

Wealth Enhancement Trust Services Sioux Falls, South Dakota $900M AUM

SIC

SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

Farther Finance Advisors's LAB Position: Q2 2026 in Review

Farther Finance Advisors increased its Standard BioTools (LAB) stake by 247% in Q2 2026, buying an estimated $771 and bringing the position to 1,147 shares worth $933. The position accounts for ﹤0.01% of the portfolio, ranked #5394.

Farther Finance Advisors first reported a position in LAB in Q1 2024 and has held it in 10 quarters since. 13 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Farther Finance Advisors held 1,147 shares of Standard BioTools worth $933 as of Q2 2026.
Farther Finance Advisors bought 816 Standard BioTools shares in Q2 2026, an estimated $771.
Standard BioTools made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5394 holding.
Farther Finance Advisors first reported a position in Standard BioTools in Q1 2024 and has held it in 10 quarters since.
13 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.